Event rates in patients starting treatment with rosuvastatin 5 mg compared to simvastatin 20 mg

Study cohorts	Drug	Intention-to-treat analysis †					Per-protocol analysis ‡
		Person-years *	Events	Incidence rate per 1000 person-years (95%CI)	Incidence rate ratio (rosuvastatin 5 mg vs simvastatin 20 mg) (95%CI)	Adjusted HR (rosuvastatin 5 mg vs simvastatin 20 mg) (95%CI)	Person-years *	Events	Adjusted HR (rosuvastatin 5 mg vs simvastatin 20 mg) (95%CI)
Men
Mortality
	Rosuvastatin 5 mg	91 705	775	8.5 (7.9–9.1)	0.85 (0.76–0.96)	0.93 (0.83–1.04)	74 800	530	1.04 (0.90–1.19)
	Simvastatin 20 mg	50 006	495	9.9 (9.1–10.8)			40 033	296
Mortality and/or hospitalization for ischemic cardiovascular and cerebrovascular diseases§
	Rosuvastatin 5 mg	91 268	1186	13.0 (12.3–13.8)	0.87 (0.79–0.95)	0.94 (0.85–1.03)	74 618	850	0.98 (0.87–1.10)
	Simvastatin 20 mg	49 721	745	15.0 (13.9–16.1)			39 926	497
Women
Mortality
	Rosuvastatin 5 mg	120 344	551	4.6 (4.2–5.0)	0.93 (0.81–1.07)	0.99 (0.86–1.14)	96 874	319	0,99 (0.82–1.20)
	Simvastatin 20 mg	63 040	310	4.9 (4.4–5.5)			49 530	177
Mortality and/or hospitalization for cardiovascular and cerebrovascular diseases§
	Rosuvastatin 5 mg	120 122	767	6.4 (5.9–6.9)	0.91 (0.81–1.02)	0.96 (0.86–1.08)	96 773	484	0.93 (0.80–1.08)
	Simvastatin 20 mg	62 897	443	7,0 (6,4–7,7)			49 478	287

CI, confidence interval; HR, hazard ratio.

^*Excluding the 1-year selection period.

^†Traditional estimation in a multivariate Cox model.

^‡Inverse probability of censoring weighting (IPCW) estimation in a multivariate Cox model.

^§Ischemic cardiovascular and cerebrovascular diseases: acute ischemic heart disease (primary or secondary hospital discharge diagnosis ICD-10 codes: I21–24) or ischemic stroke (I63, I65, I66)